Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9473480 | 0.87 | HCAR2 (0.35) | MEN1KMT2AHCAR2TSHR | |
| SCHEMBL9473606 | 0.83 | MEN1 (0.40) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL9472807 | 0.80 | ALDH1A1 (0.35) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL26386507 | 0.80 | ALDH1A1 (0.35) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL6211982 | 0.78 | MEN1 (0.36) | ALDH1A1MEN1KMT2ALMNAPOLB | |
| SCHEMBL9207485 | 0.77 | MEN1 (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL26386496 | 0.77 | ALDH1A1 (0.35) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL11376421 | 0.75 | MEN1 (0.34) | ALDH1A1MEN1KMT2ALMNAPOLB | |
| SCHEMBL22025286 | 0.74 | MEN1 (0.34) | ALDH1A1MEN1KMT2ALMNAPOLB | |
| SCHEMBL7023419 | 0.72 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155559-B2 | Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20200207772-A1 | ISOQUINOLINYLSULFONYL DERIVATIVE AND USE THEREOF | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2020-07-02 | — | — | US | disclosed |
| EP-3656772-A1 | ISOQUINOLINYLSULFONYL DERIVATIVE AND USE THEREOF | China Resources Pharmaceutical Holdings Company Limited (CN) | 2020-05-27 | — | — | EP | disclosed |
| EP-0757990-B1 | 7-(1-Pyrrolidoinyl)-3-quinolone and naphthyridone carboxylic acid derivatives, method for their preparation and for substituted mono- and bicyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions | BAYER HEALTHCARE AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| EP-0350733-B1 | 7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic-acid derivatives, method for their preparation and for substituted mono- and bi-cyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions | BAYER AG (DE) | 1997-08-20 | — | — | EP | disclosed |
| US-5607942-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0757990-A1 | 7-(1-Pyrrolidoinyl)-3-quinolone and naphthyridone carboxylic acid derivatives, method for their preparation and for substituted mono- and bicyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions | BAYER AG (DE) | 1997-02-12 | — | — | EP | disclosed |
| US-5416096-A | 7-(1-pyrrolidinyl)-3-quinolone carboxylic acid derivatives as antibacterial agents and feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-16 | — | — | US | disclosed |
| US-5241076-A | 1,4-diazatricyclo [6.3.0.0]undecanes | BAYER AKTIENGESELLSCHAFT (DE) | 1993-08-31 | — | — | US | disclosed |
| US-5177210-A | Preparation of 2,7-diazabicyclo(3.3.0)octanes | BAYER AKTIENGESELLSCHAFT (DE) | 1993-01-05 | — | — | US | disclosed |
| US-5071999-A | Preparation of 2,7-diazabicyclo[3.3.0]octanes | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-10 | — | — | US | disclosed |
| US-5059597-A | Animal growth regulators; enterobacter | BAYER AKTIENGESELLSCHAFT (DE) | 1991-10-22 | — | — | US | disclosed |
| US-4990517-A | 7-(1-pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-05 | — | — | US | disclosed |
| EP-0350733-A2 | 7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic-acid derivatives, method for their preparation and for substituted mono- and bi-cyclic pyrrolidine intermediates, and their antibacterial and feed additive compositions | BAYER AG (DE) | 1990-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207772-A1 | ISOQUINOLINYLSULFONYL DERIVATIVE AND USE THEREOF | RHOT2, ROCK2, CIT | ALDH1A1 3164/4885MEN1 3877/4885KMT2A 2564/4885 |
| US-11155559-B2 | Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity | KCNQ2, KCNQ1, KCNH3 | ALDH1A1 2790/4885MEN1 3144/4885KMT2A 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.